Fulgent Diagnostics Announces a Clinical BRCA1/BRCA2 Full Gene Sequencing Test for $500
Temple City, California (PRWEB) March 26, 2014 -- In addition to the BRCA1/BRCA2 full gene sequencing test, Fulgent Diagnostics has also added a gene rearrangement test for an additional cost of $400.
Fulgent Diagnostic's BRCA1/BRCA2 full gene sequencing test with rearrangement provides valuable information that can lead to potential treatment options that could mitigate certain risks. These options would include; additional screening, monitoring, and possible surgical options. Testing BRAC1 and BRAC2 could potentially help other family members assess their risk. Men that have these mutations also have an increased risk of breast cancer, and both men and women who have harmful BRCA1 or BRCA2 mutations may be at increased risk of additional types of cancer.
"Fulgent Diagnostics is looking at lowering the cost of genetic testing. We aim to address the needs of physicians, genetic counselors and to remove the financial barriers that have impeded complete patient care", stated lab director Dr. Harry Gao. Using massively parallel sequencing, proprietary workflow and bioinformatics, Fulgent Diagnostics has been reducing the cost of clinical sequencing since it's inception.
This test is available to institutions that apply, and are approved, for Fulgent's Diagnostic Direct Partner program. "The application process is straight forward", said Joe Roach, Vice President of Fulgent Therapeutics. Joe Roach also stated, "the one time application process can often be completed and approved in less than 48 hours. Once approved, the institution is allowed access to this tests and future test that are put into the program".
Stop by and see Fulgent Diagnostics at the ACMG conference in Nashville, booth 1012, to find out more information about the test or program or email us at: info(at)fulgentdiagnostics(dot)com or tel: 626-350-0537 x106.
For a complete list of tests available please visit: fulgentdiagnostics.com.
About: Fulgent Diagnostic is a CLIA Licensed and CAP accredited laboratory located in Temple City, California. Fulgent Diagnostics provides affordable next generation genetic tests using massively parallel processes to a global community. Tests range from cancers, common and esoteric hereditary syndromes.
Kathryn, Roach, Fulgent Therapeutics, http://www.fulgent-therapeutics.com, +1 (626) 350-0537 Ext: 106, [email protected]
Share this article